Jump Financial
KYMR icon

Jump Financial’s Kymera Therapeutics KYMR Stock Holding History

Jump Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-13,803
Closed -$1.58M – 2503
2026
Q2 		$1.58M Buy
+13,803
New +$1.19M 0.01% 986
2025
Q1 		– Sell
-9,666
Closed -$389K – 1829
2024
Q4 		$389K Sell
9,666
-1,425
-13% -$64.4K 0.01% 1199
2024
Q3 		$525K Sell
11,091
-12,426
-53% -$549K 0.01% 1085
2024
Q2 		$702K Buy
+23,517
New +$814K 0.01% 976
2021
Q2 		– Sell
-18,037
Closed -$701K – 1256
2021
Q1 		$701K Buy
+18,037
New +$1.09M 0.07% 316

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Jump Financial's KYMR Position: Q3 2026 in Review

Jump Financial sold out of Kymera Therapeutics (KYMR) in Q3 2026, closing a stake of 13,803 shares — an estimated $1.58M sold.

Jump Financial first reported a position in KYMR in Q1 2021 and held it in 5 quarters. The position peaked at $1.58M in Q2 2026. 215 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Jump Financial reported no remaining Kymera Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jump Financial sold 13,803 Kymera Therapeutics shares in Q3 2026, an estimated $1.58M.
  • Jump Financial first reported a position in Kymera Therapeutics in Q1 2021 and held it in 5 quarters.
  • Jump Financial's Kymera Therapeutics position peaked at $1.58M in Q2 2026.
  • 215 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Jump Financial's 13F filing for Q3 2026, filed 13 Nov 2026.